Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.11 – $0.15
60% from low
Exchange
OTC Link
CS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $101.0M | $125.8M | $183.8M | $251.0M | $259.9M | $254.9M | $257.1M |
| Cost of revenue | $63.5M | $84.3M | $117.4M | $161.5M | $181.5M | $185.1M | $187.8M |
| Gross profit | $37.5M | $41.5M | $66.5M | $89.4M | $78.4M | $69.8M | $69.3M |
| Gross margin | 37.1% | 33.0% | 36.2% | 35.6% | 30.2% | 27.4% | 27.0% |
| R&D | $1.5M | $1.8M | $2.4M | $3.9M | $6.0M | $5.6M | $4.3M |
| Operating income | $15.6M | $15.7M | $25.2M | $33.2M | $20.2M | $9.3M | $14.6M |
| EBITDA | $29.8M | $34.0M | $51.6M | $69.9M | $57.2M | $49.9M | $49.5M |
| Net income | $18.4M | $17.1M | $18.4M | $25.7M | $10.8M | $791.0K | $6.8M |
| Net margin | 18.2% | 13.6% | 10.0% | 10.3% | 4.2% | 0.3% | 2.6% |
| EPS (diluted) | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $286M | $0.00 | $0.00–$0.00 | 1 |
| 2027 | $312M | $0.01 | $0.01–$0.01 | 1 |
| 2028 | $331M | $0.01 | $0.01–$0.01 | 1 |
Forward consensus · source: Financial Modeling Prep
FRONTAGE HLDGS CORP
No one on the platform currently holds FGHQF.
No tracked institution reports a position in FGHQF as of their last filing.
No one on the platform has traded FGHQF yet.
| $342M |
| — |
| HNSBFHansa Biopharma AB | $2.90 | +0.00% | $246M | — |
| IDGXFIntegrated Diagnostics Holdings plc | $0.49 | -14.17% | $288M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.